Limits...
Polymorphism of DNA methyltransferase 3B -149C/T and cancer risk: a meta-analysis.

Zhu J, Du S, Zhang J, Wang Y, Wu Q, Ni J - Med. Oncol. (2014)

Bottom Line: Published data on the association between DNA methyltransferase (DNMT) 3B -149C/T polymorphism and cancer risk remain inconclusive.We used odds ratios (ORs) with 95 % confidence intervals (CIs) to assess the strength of the association.Our meta-analysis suggested that DNMT3B -149C/T polymorphism was associated with the risk of head and neck cancer under heterozygote comparison (OR 0.73, 95 % CI 0.59-0.90) and dominant model (OR 1.75, 95 % CI 0.62-0.92), although no evidence of association between DNMT3B -149C/T polymorphism and cancer risk was observed as we compared in the pooled analyses (homozygote comparison: OR 0.96, 95 % CI 0.86-1.09; heterozygote comparison: OR 1.07, 95 % CI 0.86-0.32; dominant model: OR 1.03, 95 % CI 0.85-1.25; recessive model: OR 0.93, 95 % CI 0.8-1.08).

View Article: PubMed Central - PubMed

Affiliation: Department of Respiratory and Critical Care Medicine, The First People's Hospital of Yichang, 2# Jiefang Road, Yichang, 443000, Hubei Province, China.

ABSTRACT
Published data on the association between DNA methyltransferase (DNMT) 3B -149C/T polymorphism and cancer risk remain inconclusive. To derive a more precise estimation for this association, we performed a meta-analysis of 5,903 cancer cases and 8,132 controls from 22 published case-control studies. We used odds ratios (ORs) with 95 % confidence intervals (CIs) to assess the strength of the association. Our meta-analysis suggested that DNMT3B -149C/T polymorphism was associated with the risk of head and neck cancer under heterozygote comparison (OR 0.73, 95 % CI 0.59-0.90) and dominant model (OR 1.75, 95 % CI 0.62-0.92), although no evidence of association between DNMT3B -149C/T polymorphism and cancer risk was observed as we compared in the pooled analyses (homozygote comparison: OR 0.96, 95 % CI 0.86-1.09; heterozygote comparison: OR 1.07, 95 % CI 0.86-0.32; dominant model: OR 1.03, 95 % CI 0.85-1.25; recessive model: OR 0.93, 95 % CI 0.8-1.08). More studies are needed to detect DNMT3B -149C/T polymorphism and its association with cancer in different ethnic populations incorporated with environment exposures in the susceptibility of different kinds of cancer.

Show MeSH

Related in: MedlinePlus

Meta-analysis with a fixed effects model for the ORs of cancer risk associated with DNMT3B −149 C/T (CC/CT vs. TT)
© Copyright Policy - OpenAccess
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4247848&req=5

Fig1: Meta-analysis with a fixed effects model for the ORs of cancer risk associated with DNMT3B −149 C/T (CC/CT vs. TT)

Mentions: The evaluation of association between DNMT3B −149C/T polymorphism and cancer risk is presented in Table 2. There was no significant association between DNMT −149C/T polymorphism and the risk of cancer (CC vs. TT: OR 0.96, 95 % CI 0.86–1.09; P = 0.1, I2 = 34 % for heterogeneity). In the stratified analysis by cancer type, DNMT3B −149C/T polymorphism was relative with a significantly increased risk of head and neck cancer in two tested models (CT vs. TT: OR 0.73, 95 % CI 0.59–0.9; P = 0.33, I2 = 0 % for heterogeneity; CC/CT vs. TT: OR 0.76, 95 % CI 0.61–0.93; P = 0.3, I2 = 7 % for heterogeneity; Fig. 1). However, no significant elevated risk of colorectal cancer, gastric cancer, hepatocellular cancer, breast cancer and other cancers with this polymorphism were shown in overall comparisons. At the same time, we failed to find significant main effects for DNMT3B −149C/T polymorphism on cancer risk in different genetic models when stratified according to ethnicity or sources of controls.Table 2


Polymorphism of DNA methyltransferase 3B -149C/T and cancer risk: a meta-analysis.

Zhu J, Du S, Zhang J, Wang Y, Wu Q, Ni J - Med. Oncol. (2014)

Meta-analysis with a fixed effects model for the ORs of cancer risk associated with DNMT3B −149 C/T (CC/CT vs. TT)
© Copyright Policy - OpenAccess
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4247848&req=5

Fig1: Meta-analysis with a fixed effects model for the ORs of cancer risk associated with DNMT3B −149 C/T (CC/CT vs. TT)
Mentions: The evaluation of association between DNMT3B −149C/T polymorphism and cancer risk is presented in Table 2. There was no significant association between DNMT −149C/T polymorphism and the risk of cancer (CC vs. TT: OR 0.96, 95 % CI 0.86–1.09; P = 0.1, I2 = 34 % for heterogeneity). In the stratified analysis by cancer type, DNMT3B −149C/T polymorphism was relative with a significantly increased risk of head and neck cancer in two tested models (CT vs. TT: OR 0.73, 95 % CI 0.59–0.9; P = 0.33, I2 = 0 % for heterogeneity; CC/CT vs. TT: OR 0.76, 95 % CI 0.61–0.93; P = 0.3, I2 = 7 % for heterogeneity; Fig. 1). However, no significant elevated risk of colorectal cancer, gastric cancer, hepatocellular cancer, breast cancer and other cancers with this polymorphism were shown in overall comparisons. At the same time, we failed to find significant main effects for DNMT3B −149C/T polymorphism on cancer risk in different genetic models when stratified according to ethnicity or sources of controls.Table 2

Bottom Line: Published data on the association between DNA methyltransferase (DNMT) 3B -149C/T polymorphism and cancer risk remain inconclusive.We used odds ratios (ORs) with 95 % confidence intervals (CIs) to assess the strength of the association.Our meta-analysis suggested that DNMT3B -149C/T polymorphism was associated with the risk of head and neck cancer under heterozygote comparison (OR 0.73, 95 % CI 0.59-0.90) and dominant model (OR 1.75, 95 % CI 0.62-0.92), although no evidence of association between DNMT3B -149C/T polymorphism and cancer risk was observed as we compared in the pooled analyses (homozygote comparison: OR 0.96, 95 % CI 0.86-1.09; heterozygote comparison: OR 1.07, 95 % CI 0.86-0.32; dominant model: OR 1.03, 95 % CI 0.85-1.25; recessive model: OR 0.93, 95 % CI 0.8-1.08).

View Article: PubMed Central - PubMed

Affiliation: Department of Respiratory and Critical Care Medicine, The First People's Hospital of Yichang, 2# Jiefang Road, Yichang, 443000, Hubei Province, China.

ABSTRACT
Published data on the association between DNA methyltransferase (DNMT) 3B -149C/T polymorphism and cancer risk remain inconclusive. To derive a more precise estimation for this association, we performed a meta-analysis of 5,903 cancer cases and 8,132 controls from 22 published case-control studies. We used odds ratios (ORs) with 95 % confidence intervals (CIs) to assess the strength of the association. Our meta-analysis suggested that DNMT3B -149C/T polymorphism was associated with the risk of head and neck cancer under heterozygote comparison (OR 0.73, 95 % CI 0.59-0.90) and dominant model (OR 1.75, 95 % CI 0.62-0.92), although no evidence of association between DNMT3B -149C/T polymorphism and cancer risk was observed as we compared in the pooled analyses (homozygote comparison: OR 0.96, 95 % CI 0.86-1.09; heterozygote comparison: OR 1.07, 95 % CI 0.86-0.32; dominant model: OR 1.03, 95 % CI 0.85-1.25; recessive model: OR 0.93, 95 % CI 0.8-1.08). More studies are needed to detect DNMT3B -149C/T polymorphism and its association with cancer in different ethnic populations incorporated with environment exposures in the susceptibility of different kinds of cancer.

Show MeSH
Related in: MedlinePlus